ClinicalTrials.gg
CompletedNCT07388511Updated Apr 20, 2026

A Study of Elenestinib in Healthy Adult Female Participants

A Phase 1 interventional study of Elenestinib and Midazolam in Healthy Participants, sponsored by Blueprint Medicines Corporation. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive.

Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Blueprint Medicines Corporation is the lead sponsor of 32 studies on the registry; 6 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 3 (21%) have results posted.

First submitted after Blueprint Medicines Corporation became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy, adult, female, 18-65 years of age, inclusive, at the screening visit that meet either of the following criteria:
  • female, defined as amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status at the screening visit (note that participants may have had hysterectomy, bilateral salpingectomy, or bilateral tubal ligation).
  • Female status-post bilateral oophorectomy.
  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 6 months prior to the first dosing.
  • ≥ 18.0 and ≤ 35.0 kg/m2 at the screening visit.
  • Medically healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, and (ECGs), as deemed by the principal investigator (PI) or designee.

Key Exclusion Criteria:

  • History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
  • History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
  • History or presence of alcohol or drug abuse (except for the occasional use of cannabis products) within the past 1 years prior to the first dosing.
  • History or presence of cannabis use within the past 3 months prior to the first dosing.
  • History or presence of or idiosyncratic reaction to elenestinib, midazolam, combined oral (levonorgestrel/ethinyl estradiol), or related compounds.
  • Unable to refrain from or anticipates the use of:
  • Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing.
  • Any drugs known to be moderate or strong inducers of enzymes and/or P-gp beginning at least 28 days prior to first dosing.
  • Any drugs known to increase or decrease levels of SHBG, including any oral, topical, or intravaginal hormone-containing product, within 12 weeks prior to the first dosing.

Other protocol-defined inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Elenestinib, Midazolam, and Levonorgestrel/Ethinyl Estradiol

    Drug: Elenestinib · Drug: Midazolam · Drug: Levonorgestrel/Ethinyl Estradiol

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t)

    Time frame: Up to 27 days

  2. Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)

    Time frame: Up to 27 days

  3. Percent of AUC0-inf extrapolated (AUC%extrap)

    Time frame: Up to 27 days

  4. Maximum observed concentration (Cmax)

    Time frame: Up to 27 days

  5. Time to reach Cmax (Tmax)

    Time frame: Up to 27 days

  6. Apparent first-order terminal elimination half-life (t1/2)

    Time frame: Up to 27 days

  7. Apparent total plasma clearance after oral administration (CL/F)

    Time frame: Up to 27 days

  8. Apparent volume of distribution during the terminal elimination phase after oral administration (Vz/F)

    Time frame: Up to 27 days

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: From first dose to date of last dose plus 30 days (up to approximately 7 weeks)

07

Study locations

1 site
  • Celerion, Inc
    Tempe, Arizona 85282, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Apr 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 5, 2026
StartActual
Feb 5, 2026
Primary completionActual
Apr 2, 2026
CompletionActual
Apr 2, 2026
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07388511
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Feb 5, 2026
Primary completion
Apr 2, 2026
Completion
Apr 2, 2026
Last update
Apr 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elenestinib · Levonorgestrel · Ethinyl Estradiol

Start the discussion